RG7787 is a mesothelin-targeted immunotoxin designed to have low-immunogenicity, high-cytotoxic activity and fewer side effects. RG7787 kills many types of mesothelin-expressing cancer cells lines and causes tumor regressions in mice. Safety and immunogenicity of RG7787 is now being assessed in a phase I trial. To enhance the antitumor activity of RG7787, we screened for clinically used drugs that can synergize with RG7787. Actinomycin D is a potent transcription inhibitor that is used for treating several cancers. We report here that actinomycin D and RG7787 act synergistically to kill many mesothelin-positive cancer cell lines and produce major regressions of pancreatic and stomach cancer xenografts. Analyses of RNA expression show that RG7787 or actinomycin D alone and together increase levels of TNF/TNFR family members and NF-κB-regulated genes. Western blots revealed the combination changed apoptotic protein levels and enhanced cleavage of Caspases and PARP.
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cancer therapy | apoptosis | immunotherapy | pancreatic cancer | mesothelioma R ecombinant immunotoxins (RITs) are chimeric proteins that contain an antibody fragment directed against a tumorselective surface antigen attached to a protein toxin. We have constructed immunotoxins by attaching a 38 kDa fragment of Pseudomonoas exotoxin A (PE38) to the Fv portion of mAb that binds to cancer cells but not to essential tissues (1, 2) . RITs kill cells by ADP-ribosylating and inactivating elongation factor (EF)-2, leading to protein synthesis arrest, a fall in MCL-1 levels, and induction of apoptosis (3, 4) . SS1P is a RIT that targets mesothelin, a protein highly expressed on mesothelioma, pancreatic, ovarian, lung, and stomach cancers. Because SS1P contains a bacterial toxin, it is immunogenic and can only be given for one treatment cycle to most patients. However, when combined with pentostatin and cyclophosphamide to suppress antibody formation, SS1P has produced major and prolonged tumor regressions in some patients with advanced chemo-refractory mesothelioma (5) (6) (7) .
RG7787 (now named LMB-100) is in clinical trials for refractory pancreatic cancer (NCT02810418) and mesothelioma (NCT02798536). It is a derivative of SS1P containing mutations that make it less immunogenic, more active in killing target cells, and better tolerated by patients (7) . The targeting moiety of RG7787 is a humanized antimesothelin Fab; its effector moiety is a 24-kDa ADP ribosylation domain of PE fused via a furin cleavable linker to the Fab. The domain III variant used in RG7787 contains mutations that silence many human B-cell epitopes and some T-cell epitopes. RG7787 is cytotoxic to many mesothelin-expressing cell lines and when combined with pacilitaxel produces complete remissions in pancreatic cancer-bearing mice (7) .
The mechanism by which immunotoxins kill cells is not completely understood. After binding to specific receptors, immunotoxins enter cells by endocytosis, and in the endocytic compartment, the furin separates the Fv from the toxin. Then the toxin is transferred in a retrograde fashion through the Golgi and endoplasmic reticulum into the cytosol. There the toxin catalyzes the ADP ribosylation of EF-2, leading to protein synthesis arrest and apoptosis (4) .
Actinomycin D (Act D) is a polypeptide antibiotic isolated from the genus Streptomyces. Act D intercalates into DNA, preventing the progression of RNA polymerases (8, 9) . It is widely used as a transcription inhibitor. RNA polymerase I, catalyzing ribosomal RNA transcription, is most sensitive to Act D (IC 50 , 0.05 μg/mL); RNAP II (0.5 μg/mL) and RNAP III (about 5 μg/mL) are less sensitive (9) . Nanomolar concentrations of Act D block transcription of RNA polymerase I and induce nucleolar stress by interfering with ribosome biogenesis (10) (11) (12) . Act D is the first antibiotic used for treating cancer; these cancers include gestational trophoblastic neoplasia, Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, and NPM1-mutated acute myeloid leukemia (13) . The mechanism by which Act D causes tumor cell death is not established.
Many anticancer drugs exert their effects by triggering apoptosis (14, 15) . Apoptosis can be triggered by the extrinsic (receptor) pathway or at the mitochondrial level by the intrinsic pathway. Activation of members of the TNFR superfamily, such as FAS, TRAILR1 and R2, TNFR, and CD137, results in recruitment of death domain proteins and caspase-8 activation, which can result in the cleavage of Bid and activation of the intrinsic apoptotic pathway (16) . TNFR superfamily activation leads to activation of NF-κB, a key regulatory protein that can initiate cell death (17) (18) (19) .
Significance
Because effective cancer therapy usually requires a combination of drugs, we searched for clinically used anticancer agents that would enhance the activity of immunotoxin RG7787 so they could be combined in humans. We show here that actinomycin D activates the extrinsic pathway of apoptosis and acts synergistically with RG7787 to kill a variety of cancer cell lines and cause striking tumor regression in mice. These data indicate that combining immunotoxins like RG7787 that kill cells by inhibiting protein synthesis with actinomycin D is a useful strategy to enhance their antitumor activity in humans.
To improve the antitumor activity of RG7787, we have screened nine DNA-damaging agents in clinical use that enhance RG7787 action. We report here that Act D and RG7787 act synergistically to increase killing of many mesothelin-expressing cancers and cause major tumor regressions in tumor-bearing mice. These data support the combined use of these agents in ongoing trials with RG7787.
Results
Act D Enhances Killing of KLM1 Cells by RG7787. We screened seven DNA-damaging drugs and found that Act D dramatically synergized with RG7787 to kill 25 cancer cell lines (lung, pancreas, ovary) ( Fig. S1 and Table S1 ). To determine the cytotoxic mechanism, we stained the treated cells with annexin V and 7AAD and used flow cytometry to measure cell apoptotic death. Fig. 1A shows that 9% of cells treated for 24 h with RG7787 at 100 ng/mL had died, Act D alone at 10 ng/mL did not cause cell death, but the combination was very effective, killing about 20% of the cells. To examine the effect of lower concentrations of these agents, we extended the treatment time to 72 h (Fig. 1B) or 96 h (Fig. 1C) . Under both conditions, the combination was more than additive, and 60-75% of the cells underwent apoptosis. Fig. 1D shows photomicrographs of KLM1 cells after 4 d of treatment with RG7787 (10 ng/mL) or Act D (10 ng/mL) or both. Cells treated with Act D alone appeared larger and thinner, and there were fewer cells, indicating inhibition of cell growth. With RG7787 many cells died and small clusters of cells survived. In the combination group, only a few nonviable rounded cells were present on day 4, which did not grow out when the drugs were removed (Fig. 1D ).
Act D Accelerates Killing of Tumor Cells. Because immunotoxin RG7787 has a relatively short half-life in the circulation, it is important that cells are killed after a short exposure to RG7787 (20) . To evaluate if Act D treatment shortens the time needed for RG7787 to kill cells, KLM1 cells were treated with low doses of RG7787 in combination with Act D for 6, 24, or 48 h, and the cells were transferred to drug-free medium and followed. Fig. 1E shows that exposure to each agent alone for 6 h had little effect on the cells, but the combination decreased cell numbers. Treatment with either agent for 24 or 48 h slightly decreased cell numbers, but there were very few cells after combination treatment for 24 h and no cells after 48 h of treatment. To verify that the treated cells were dying by apoptosis and to quantify the effect, we used flow cytometry and stained cells with annexin V and 7AAD. Table 1 shows data from eight cell lines of diverse cancer types: pancreas, breast, stomach, lung, cervix, and mesothelioma. With all these cancer types, we found that killing by the combination was more than additive.
The combination of Act D and RG7787 also caused rapid killing of pancreatic cancer AsPC-1 cells (Fig. S3A) . In 6 h, the combination killed equivalent numbers of cells as RG7787 single treatment for 24 or 48 h. In addition, combined treatment for 24 or 48 h completely killed almost all of the cells. Hay and MKN28 cells were also efficiently killed by low doses of RG7787 when combined with Act D (Fig. S3 B and C) .
Mouse Experiments. To evaluate the effect of combination treatment, we used KLM1 pancreatic tumors, which we previously showed were mainly growth-inhibited by RG7787 alone (21) . Fig.  2A shows that tumors had reached 100 mm 3 on day 6 after treatment was started. The PBS control group continued to grow and reached about 500 mm 3 on day 15. Tumors in the RG7787 group had a slight decrease in size after the first cycle of treatment but had grown significantly by day 22. Treatment with Act D slowed tumor growth but did not cause tumor shrinkage. However, tumors in the combination group started to shrink from the second day of treatment. On day 30, five of eight mice had no measurable tumors, and three of eight had very small tumors below 20 mm 3 . On day 41, two mice still had no measurable tumors. The other six tumors started to grow, but all were below 50 mm 3 . No mice died from the therapy, although some mice in the combination group lost up to 10% of their weight during the first few days of treatment. They had fully recovered by the end of the second cycle of treatment. This experiment was repeated with similar results. We did not try three cycles of treatment. We also examined the effect of RG7787 and Act D on MKN28 tumors (Fig. 2B) . MKN28 tumors grew slower than KLM1 tumors and had reached 100 mm 3 on day 9, when we started treatment. Tumors in the control group (n = 6) reached 500 mm 3 on day 20. Tumor growth slowed in both the RG7787 group (n = 6) and the Act D group (n = 6), but tumor shrinkage was not observed. In contrast, with combination treatment (Combo, n = 6), the tumors decreased in size up until day 21 and then began to regrow. The combination significantly inhibited the tumor growth much more than RG7787 or Act D single treatment (P < 0.01) from day 15 to day 28.
Mechanism Studies. One way to increase immunotoxin action is to increase the rate and amount of immunotoxin taken into the cell. To measure uptake, cells were exposed to Alexa Fluor 647-RG7787, and the amount accumulated was measured in a flow cytometer. Fig. 3A shows that the uptake of Alexa-RG7787 is not changed by exposure to Act D when measured from 20 min to 3 h. After internalization and furin cleavage, the toxin is transferred to the endoplasmic reticulum and then to the cytosol, where it ADP-ribosylates EF-2. To determine if the modification and inactivation of EF-2 was stimulated by Act D treatment, cells were treated for 2, 6, and 24 h, and cell lysates were prepared for analysis of the state of EF-2. In extracts of untreated cells, EF-2 was modified by NAD-biotin in the presence of toxin, and the modified EF-2-biotin was detected on a Western blot (Fig. 3B) . In cells treated with immunotoxin, EF-2 becomes resistant to modification with NAD-biotin, because the site is already modified. Fig. 3B shows that at 2 and 6 h, the EF-2 in RG7787-treated cells is resistant to ADP ribosylation and that Act D has no effect on this modification. Treatment for 24 h with Act D slightly decreased ADP ribosylation, but the combination with RG7787 did not further decrease levels of ADP-EF-2 (24 h longer exposure). This indicates that Act D does not affect the toxin trafficking to the endoplasmic reticulum, transfer to the cytosol, or EF-2 modification and must act on some subsequent step to arrest protein synthesis.
Act D and RG7787 Changed Apoptotic Proteins. Western blots were performed to determine which apoptotic proteins were changed by this treatment (Fig. 4A) . The combination greatly increased levels of PARP, tBID, and Caspase-3, -8, and -9, all of which are proapoptotic proteins. Act D by itself had very little effect on these proteins, except for elevating BIM, which is antiapoptotic, but BIM levels were decreased by RG7787. RG7787 alone lowered levels of MCL-1, BIM, and BCLxl and had small effects on Caspase-8 and -9 and on PARP.
RNA Changes Induced by Act D and RG7787. Act D is an effective inhibitor of RNA polymerase 1, and this inhibition results in a decrease in the synthesis of ribosomal RNA (9) . To determine if the low concentrations of Act D used in our experiments affected levels of RNA encoding proteins in the apoptotic pathway, we used a RNA array containing 84 different proapoptotic and antiapoptotic genes. KLM1 and RH16 cells were treated with Act D, RG7787, or both for 24 h and prepared RNA for analysis. The ratios of RNA levels compared with untreated cells are shown in Table S2 . For both cell types, the levels of RNA for the control house-keeping genes (ACTB, B2M, GAPDH, RPLP0, or HPRT1) were largely unaffected. This result indicates that at the low concentration of Act D used in these experiments, there is not an overall inhibition of RNA synthesis. Unexpectedly, we There is a statistically significant difference between RG7787 and combination treatment beginning from day 11 (*P < 0.001, n = 8 per treatment group). (B) MKN28 cells were similarly injected and treated as in A at the indicated days. There are statistically significant differences between RG7787 and combination (*P ≤ 0.01, n = 6) starting from day 15 until the end of the experiment. Tumor cells were cultured with Act D at either 2.5 ng/mL (Hay), 5 ng/mL (RH16), 10 ng (KLM1, KB, MKN28, HCC70, NUGC4), or 15 ng/mL (L55) with or without RG7787 at 5 ng/mL (KLM1, KB, Hay, MKN28, NUGC4), 10 ng/mL (HCC70, RH16), or 50 ng/mL (L55) for 3 or 4 d (RH16). Cell death was determined by FACS analysis after staining of annexin V and 7AAD. The data were generated from two or three separate experiments.
observed that the level of many RNAs is increased by treatment with Act D or RG7787 or both. RNAs that changed over threefold are listed in Table 2 . Act D produced dramatic increases in KLM-1 cells in many members of the TNF and TNFR superfamily, including TNFα and TNFβ, DR2, TNFR2, CD137, and CD27. Other genes whose expression is elevated by Act D are NF-κB target genes (BCL2A1, CIAP2, and GADD45α). In RH16 cells, there was an increase in Fas and CD27 but not other TNFR family members. RG7787 increased the levels of many of the same RNAs, and they were also elevated in cells treated with the combination. However, there were differences. For example, CD27 was elevated by Act D and the combination but was decreased by RG7787 alone.
To confirm the array findings, we chose several genes with the largest changes and performed real time-PCR using KLM1 RNA. As seen in Table S3 , TNFα and TNFβ were elevated from 10-to 98-fold by either Act D, RG7787, or the combination. The TNFR family member CD137 was elevated 56-fold by RG7787 alone, and DR5 increased two-to threefold. The other NF-κB target genes-BCL2A1, BIK, CIAP2, and GADD45α-were also found to be elevated. We also performed real-time PCR with RNA from RH16 cells and confirmed the increased expression of the same genes as seen in the apoptotic RNA array experiments with RH16 cells (Table S2) .
Changes in Proteins of the NF-κB Pathway. Because activation of the TNF/TNFR pathway increases the activity or expression of NF-κB, we examined levels of proteins in the NF-κB pathway using KLM1 cells. Fig. 4B shows that P-MAPK (T202/Y204), the kinase that phosphorylates NF-κB, is undetectable in control cells, slightly increased in Act D-treated cells, dramatically elevated by RG7787, and further elevated by the combination. We also observed that total MAPK is increased by treatment with Act D, RG7787, or the combination. P-NF-κB (S536), which is the activated form of NF-κB, was also increased by Act D, RG7787, or combination treatment (1.8-, 2.7-, and 3.3-fold, respectively). Total NF-κB was only slightly increased (less than twofold). To confirm that NF-κB was activated, we isolated the nuclear fraction of cells, in which the activated form of NF-κB accumulates. As shown in Fig. 4C , nuclear NF-κB levels were increased 3.1-fold by Act D treatment, and over 50-fold by RG7787, and by combination treatment.
Role of TNF Family Members. Because RNA and protein of members of the TNF/TNFR family were increased by Act D, we investigated if TNFα family members could have a direct role in RG7787-mediated cell killing. As shown in Fig. 5A , cells treated with either FASL or Trail or TNFα did not undergo cell death. However, when combined with RG7787, these agents increased cell death but not to the extent produced by Act D.
Effect of Act D with Other Inhibitors of Protein Synthesis. There are a variety of protein toxins that kill cells by inhibiting protein synthesis. Diphtheria toxins (DPs) like PE ADP-ribosylates EF-2, whereas Gelonin inactivates the 60S ribosomal subunit. These toxins are also used to make immunotoxins (22, 23) . To determine if there is also enhancement by Act D, KLM-1 cells were exposed to Act D and various toxins for 72 h and cell death was measured by flow cytometry. Because we do not have immunotoxins containing these toxins, we compared their activities with native PE. We find that killing of cells by Act D combined with PE or DT or Gelonin is more than additive (Fig. 5B) . These data also show that Act D-stimulated cell killing is not mesothelin-dependent. Fig. 4 . Western blot analysis of apoptotic proteins and signaling molecules. (A) Apoptotic proteins changed by Act D and RG7787. KLM1 cells were treated with 10 ng/mL Act D with or without RG7787 for 24 h, and cell lysates were analyzed by Western blot using anti-MCL1, anti-BCLxl, anti-Bim, anti-Bid, anti-cleaved Caspase-3, anti-cleaved Caspase-8, anti-cleaved Caspase-9, and anti-PARP. Actin is the loading control. (B) Increased level of TNF/ TNFR superfamily and activation of NF-κB. Total protein lysates from KLM1 cells treated with 10 ng/mL Act D with or without 100 ng/mL RG7787 were blotted with anti-DR5, anti-CIAP2, anti-P-MAPK (p38), anti-MAPK (p38), anti-NF-κB (p65), or P-NF-κB (p65). Actin is the normalization for the loading. (C) After KLM1 cells were treated as above, the nuclear fraction was isolated using a cyto/nuc fractionation kit (Pierce). The nuclear fraction was used for Western blot with anti-total NF-κB and anti-HDAC2 (loading control). The relative numbers were obtained from scanning the Western blot using NIH image, and the ratios were calculated by setting the untreated control as 1. SE, short exposure. 
Discussion
We have found that Act D has remarkable synergy with immunotoxins targeting mesothelin-expressing malignancies. RNA and protein analyses showed that cells treated with RG7787 activated both the intrinsic and extrinsic apoptotic pathways. The synergy was found in various epithelial tumors with mesothelin expression. We also found the stimulatory effect of Act D is not restricted to PE-containing immunotoxins, because Act D also enhanced the killing of cells by other toxins that inhibit protein synthesis.
Act D is an old drug developed before apoptosis and other mechanisms of cell death were elucidated. It was developed as an anticancer agent in the 1950s and approved for treatment of humans in the 1960s (8) . It is known that Act D can bind to GCrich regions in DNA duplexes and is especially effective at disruption of ribosome RNA biogenesis (9, 10) . It is also known that Act D is cytotoxic when used at high concentrations. In this study, we used relatively low (5-10 ng/mL) concentrations of Act D. Analysis of RNA arrays showed that the levels of RNA for the majority of the 86 genes in the apoptotic array, including several house-keeping genes, were not decreased in a major way compared with untreated cells. A decrease should have been observed if overall RNA synthesis had been inhibited. Instead, for many genes the levels of RNA were increased. The most affected genes are TNF/TNFR family members [TNFα, TNFβ, TNFR2 (KLM1), CD27, CD70 (KLM1), CD137 (KLM1), and TRAILR2/ DR5, FAS (RH16)], NF-κB-regulated genes (BCL2A1, CIAP2, BCL10, GADD45α), caspase family members (Caspase-1, -3, -5, -7, -9, and -10, which vary between the two cell lines), and others (BIM and RIPK2). Both BIM RNA and protein were elevated by Act D treatment but not by RG7787. BIM is located in mitochondria and plays an important role in promoting apoptosis (24) .
It is noteworthy that GADD45α is a target of both NF-κB and p53. It has been shown that Act D can stabilize p53 in the nucleolus and that targets of P53 are activated (10, 25) . We found that Act D has very little effect on total NF-κB protein, but it enhances phosphorylation of NF-κB and its accumulation in the nucleus. It is likely the dramatic increase in GADD45α RNA could be due to both p53 and NF-κB accumulation in the nucleus.
We previously reported that immunotoxins targeting mesothelin-expressing cells sensitize the cells to killing by TRAIL (26), but we did not examine the mechanism of this effect. Our finding that RG7787 increases expression of TNFα, TNFβ, FAS, CD127, and DR5 and DR5 protein provides an explanation for that result. We also found that RG7787 activated the NF-κB pathway. NF-κB RNA increased in the apoptotic arrays from both KLM1 and RH16 cells (Table S1 ). Also NF-κB p65 phosphorylation and total NF-κB in the nuclear fraction were elevated. Expression of BCL10, CIAP2, and two NF-κB-regulated genes was also increased. It was recently reported that loss of diphthamide, which is an essential component for EF-2-ADP ribosylation, activates NF-κB and renders cells hypersensitive to TNF-mediated apoptosis (27) . It is also possible that the arrest of protein synthesis caused by RG7787 induces cell stress, activates MAPK P38, and leads to phosphorylation of NF-κB, thereby sensitizing cells to apoptosis.
When we compared the RNAs that were increased by treatment with Act D and RG7787, we found many of the same RNAs were increased, suggesting that the two agents have overlapping mechanisms of action. Genes whose expression was increased include many members of the BCL-2 family (BIM, BID, KLM1 or RH16 cells were treated with Act D (KLM1, 10 ng/mL; RH16, 5 ng/mL) or RG7787 (KLM1, 100 ng/mL; RH16, 200 ng/mL) for 24 h. Then total RNA was isolated and apoptotic array performed. The numbers are generated using webbased data analysis (Qiagen) by setting the untreated control as 1 and using ACTB, B2M, GAPDH, HPRT1, and RPLP0 as the internal control. The genes that changed over threefold were selected and presented in the table.
BCL10, and BCL2A1), the Caspase family [Caspase-1 (RH16)], Caspase-10, Caspase-5, and Caspase-7 (KLM1)], and members of the TNF and TNFR family [TNFα and TNFβ (RH16), CD137, DR5, TNFR2 (KLM1), and Fas (RH16)]. These changes occurred in both KLM-1 and RH16 cells, indicating the changes are not limited to one type of cancer cell. In some but not all cases, the increase was larger in doubly treated cells (also seen in Fig. S3 ). The importance of the variable increase between singly and doubly treated cells is not clear, because we only measured RNA levels in cells after a 24-h treatment and some cells may have been dying, which could alter RNA levels. Possibly the increase in RNA will be larger in doubly treated cells.
The mechanism by which Act D and RG7787 act synergistically to kill target cells is complex. Most prominently, Act D dramatically enhanced RG7787-induced increases of cleaved Caspase-3, -8, and -9 and PARP. The enhancement could come from activation of NF-κB-mediated signaling. Secondly, Act D can interfere with ribosomal biogenesis and causes stabilization of P53 in the nucleolus (25) . Increased P53 was shown to orchestrate a transcriptional response to stress and cause cell-cycle arrest and cell death (12) . We observed an increase of both p53 and p53BP RNA in the KLM1 cells. We also found that the p53 responsive gene GADD45α increased in KLM1 and RH16 cells, which can lead to growth arrest. Because the addition of TNFα, FASL, or Trail produced only a small increase in cell death when combined with RG7787 whereas Act D addition is very potent (Fig. 5A) , we conclude that Act D enhancement of RG7787 cytotoxic activity involves more genes and pathways than just death receptor-mediated cell death. Finally, our data strongly support the use of Act D to enhance immunotoxin action in humans.
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